Torrent Pharmaceuticals, a Rs.4000 crore Ahmedabad based pharma major, has posted impressive financial performance during the first quarter ended June 2014. Its net profit has taken a quantum jump of 71.8 per cent and touched to Rs.256 crore as against Rs.149 crore in the similar quarter of last year. Its net sales increased by 20.9 per cent to Rs.1092 crore from Rs.903 crore. With higher net profit, its EPS worked out to Rs.15.12 as compared to Rs.8.81 in the last period. EBDITA improved by 82.4 per cent to Rs.394 crore from Rs.216 crore in the last period.

Its domestic formulation business improved by 13 per cent to Rs.356 crore and international business grew by 36 per cent to Rs.733 crore. Its revenue in US improved by 138 per cent and that in Brazil moved up by 12 per cent. Similarly, its sales in Europe increased by 17 per cent. The sales in rest of the world including Russia & CIS operations recorded a degrowth of 12 per cent.

The company acquired Indian branded formulations business of Elder Pharmaceuticals for a consideration of about Rs.2,000 crore.